Article Text
Statistics from Altmetric.com
Clinical case
A 27-year-old man, receiving his 27th dose of natalizumab monotherapy for multiple sclerosis (MS), tested positive for the anti-JCV (John Cunningham virus) antibody with a low index (0.23). Five days after his 30th dose, he developed horizontal diplopia. An MR scan of the brain identified a tumefactive lesion in the right middle cerebellar peduncle, with no enhancement, and was interpreted as an MS attack (figure 1). He received two cycles of intravenous methylprednisolone but progressed with dysarthria and tetraplegia. Less than 3 months later, MR scan of the brain showed progressive expansion of the previous lesion, affecting the pons, both the right and left cerebellar peduncles, and the cerebellum (figure 2). Cerebrospinal fluid (CSF) analysis showed a strongly positive JCV PCR (>1 300 000 DNA copies/mL). Pembrolizumab was administered (2 mg/kg body weight intravenously, once) but no clinical response at 6-month follow-up (Expanded Disability Status Scale - EDSS 9.5).
Footnotes
Contributors DAP: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data. LG: drafting/revision of the manuscript for content; major role in the acquisition of data; and analysis or interpretation of data. AQ: drafting/revision of the manuscript for content, including medical writing for content; study concept or design; and analysis or interpretation of data. CRAVS: drafting/revision of the manuscript for content and analysis or interpretation of data. RBT: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; and analysis or interpretation of data.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed by Nicholas Davies, London, UK, and Neil Scolding, Bristol, UK.
Read the full text or download the PDF:
Other content recommended for you
- MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy
- Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring
- Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
- MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
- Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies
- Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution
- Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients